Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2305
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArslan, Ugur-
dc.contributor.authorCoksevim, Metin-
dc.contributor.authorDereli, Seckin-
dc.contributor.authorDogdus, Mustafa-
dc.contributor.authorKaya, Ahmet-
dc.contributor.authorYenercag, Mustafa-
dc.date.accessioned2022-08-17T05:30:34Z-
dc.date.available2022-08-17T05:30:34Z-
dc.date.issued2020-
dc.identifier.urihttp://doi.org/10.1007/s10554-020-01973-8-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2305-
dc.description.abstractThe sacubitril/valsartan combination is an important agent used in the treatment of heart failure with reduced ejection fraction (HFrEF). Pulmonary artery stiffness (PAS) is an index developed to evaluate the pulmonary vascular bed. Changes in pulmonary vascular structures in HFrEF patients can affect PAS. In this study, we aimed to investigate the effect of sacubitril/valsartan on PAS in HFrEF patients. One hundred fifty HFrEF patients, who received sacubitril/valsartan therapy and continued for at least 6 months without interruption, were examined retrospectively. N-terminal pro-B-type natriuretic peptide levels (NT-proBNP), NYHA classes, Minnesota Living with Heart Failure Questionnaire (MLWHFQ) scores, New York Heart Association (NYHA) functional classes and echocardiograpic parameters such as left ventricular ejection fraction (LVEF), mean pulmonary artery pressure (mPAP), right ventricle myocardial performance index (RV-MPI), Tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (RV-FAC) and PAS changes were evaluated before and 6 months after sacubitril/valsartan treatment. PAS was calculated by using the maximal frequency shift and acceleration time of the pulmonary artery flow trace measured in the echocardiogram. PAS values were significantly reduced (23.8 +/- 2.8 vs 19.1 +/- 3.1 kHz/ms, p < 0.001) after the sacubitril/valsartan treatment. Sacubitril/valsartan treatment was associated with significant improvements in NYHA class and MLWHFQ scores; significant reductions in the NT-proBNP levels, mPAP, and RV-MPI, and significant increases in LVEF, TAPSE, and RV-FAC (p < 0.05). The significant reduction in the PAS value was significantly correlated with the improvements in the MLWFQ scores, NT-proBNP levels, mPAP, RV-MPI, TAPSE and RV-FAC. In HFrEF patients, switching from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan may result in reduction in PAS.en_US
dc.language.isoengen_US
dc.publisherSPRINGER, VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDSen_US
dc.relation.isversionof10.1007/s10554-020-01973-8en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHeart failure; Sacubitril; valsartan; Pulmonary artery stiffnessen_US
dc.subjectRIGHT-VENTRICULAR FUNCTION; FUNCTIONAL-CAPACITY; HYPERTENSION; ENALAPRIL; COLLAGEN; LCZ696en_US
dc.titleEffects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fractionen_US
dc.typearticleen_US
dc.relation.journalINTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGINGen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0001-8572-3571en_US
dc.contributor.authorID0000-0001-9845-7938en_US
dc.contributor.authorID0000-0002-0933-7852en_US
dc.contributor.authorID0000-0003-0090-3835en_US
dc.identifier.volume37en_US
dc.identifier.issue1en_US
dc.identifier.startpage165en_US
dc.identifier.endpage173en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.